Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10364)	6/5/1999 1:45:00 PM
From: William L. Molair II	Read Replies (2) \| Respond to of 17367

I think XOMA management feels that the mengio trial went very well and would like to capitalize on it (make a deal with another company). The trauma trial may not have very strong data and the DSMB review would probably be a "non stock price enhancing event". HOWEVER, have a successful mengio Phase III trial and a continuation of the trauma trial and maybe the stock goes up on both events. OR, have an UNsucessful mengio Phase III trial - at least you can try and temper the bad (if not devastating news) with the hopeful promise of a positive trauma trial. I could have sworn that we were looking for a DSMB trauma review in March of 1999.